Ross Penny, Benjamin Fongenie, Phillip Davis, James Sykes
{"title":"PSMA 靶向 PET 放射性药物 18F-flotufolastat 的正常器官分布：对 LIGHTHOUSE 和 SPOTLIGHT 研究的事后分析。","authors":"Ross Penny, Benjamin Fongenie, Phillip Davis, James Sykes","doi":"10.62347/INCG3525","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High-affinity radiohybrid PSMA-targeting radiopharmaceutical <sup>18</sup>F-flotufolastat (<sup>18</sup>F-rhPSMA-7.3) is newly approved for diagnostic imaging of prostate cancer. Here, we conduct a post hoc analysis of two phase 3 studies to quantify <sup>18</sup>F-flotufolastat uptake in a range of normal organs.</p><p><strong>Methods: </strong>All 718 evaluable <sup>18</sup>F-flotufolastat scans from LIGHTHOUSE and SPOTLIGHT were re-evaluated. Additionally, patients' medical records were reviewed and any patients with high tumor burden (PSA>20 ng/mL), altered biodistribution (e.g., chronic kidney disease), major anatomical changes to normal organs (e.g., nephrectomy), or any other history of cancer were excluded. A medical physicist defined volumes of interest over specific organs for evaluation of SUV<sub>mean</sub> and SUV<sub>peak</sub> per PERCIST 1.0 criteria. Normally distributed data are reported as mean (SD) and non-normally distributed data as median (IQR). The co-efficient of variation (CoV; calculated as SD/mean for normally distributed data and IQR/median for non-normally distributed data) was used to quantify variability of SUV metrics.</p><p><strong>Results: </strong>In total, scans from 546 patients (244 primary, 302 recurrent) were eligible for this analysis. All organs were considered to be normally distributed except for the bladder and spleen. In the liver, the mean SUV<sub>mean</sub> was 6.7 (SD 1.7), CoV 26%, while the bladder median SUV<sub>mean</sub> was 10.6 (IQR 11.9), CoV 112%. The mean SUV<sub>peak</sub> in the liver was 8.2 (SD 2.1), CoV 26% and median SUV<sub>peak</sub> in the bladder was 16.0 (IQR 18.5), CoV 116%.</p><p><strong>Conclusions: </strong>Physiological <sup>18</sup>F-flotufolastat uptake in normal organs was broadly consistent with other renally-cleared radiopharmaceuticals, which may have clinically significant implications when considering patient selection for radioligand therapy. Additionally, the bladder median SUV<sub>peak</sub> for <sup>18</sup>F-flotufolastat was lower than that previously reported for <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-DCFPyL.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 5","pages":"337-344"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578810/pdf/","citationCount":"0","resultStr":"{\"title\":\"Normal-organ distribution of PSMA-targeting PET radiopharmaceutical <sup>18</sup>F-flotufolastat: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies.\",\"authors\":\"Ross Penny, Benjamin Fongenie, Phillip Davis, James Sykes\",\"doi\":\"10.62347/INCG3525\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>High-affinity radiohybrid PSMA-targeting radiopharmaceutical <sup>18</sup>F-flotufolastat (<sup>18</sup>F-rhPSMA-7.3) is newly approved for diagnostic imaging of prostate cancer. Here, we conduct a post hoc analysis of two phase 3 studies to quantify <sup>18</sup>F-flotufolastat uptake in a range of normal organs.</p><p><strong>Methods: </strong>All 718 evaluable <sup>18</sup>F-flotufolastat scans from LIGHTHOUSE and SPOTLIGHT were re-evaluated. Additionally, patients' medical records were reviewed and any patients with high tumor burden (PSA>20 ng/mL), altered biodistribution (e.g., chronic kidney disease), major anatomical changes to normal organs (e.g., nephrectomy), or any other history of cancer were excluded. A medical physicist defined volumes of interest over specific organs for evaluation of SUV<sub>mean</sub> and SUV<sub>peak</sub> per PERCIST 1.0 criteria. Normally distributed data are reported as mean (SD) and non-normally distributed data as median (IQR). The co-efficient of variation (CoV; calculated as SD/mean for normally distributed data and IQR/median for non-normally distributed data) was used to quantify variability of SUV metrics.</p><p><strong>Results: </strong>In total, scans from 546 patients (244 primary, 302 recurrent) were eligible for this analysis. All organs were considered to be normally distributed except for the bladder and spleen. In the liver, the mean SUV<sub>mean</sub> was 6.7 (SD 1.7), CoV 26%, while the bladder median SUV<sub>mean</sub> was 10.6 (IQR 11.9), CoV 112%. The mean SUV<sub>peak</sub> in the liver was 8.2 (SD 2.1), CoV 26% and median SUV<sub>peak</sub> in the bladder was 16.0 (IQR 18.5), CoV 116%.</p><p><strong>Conclusions: </strong>Physiological <sup>18</sup>F-flotufolastat uptake in normal organs was broadly consistent with other renally-cleared radiopharmaceuticals, which may have clinically significant implications when considering patient selection for radioligand therapy. Additionally, the bladder median SUV<sub>peak</sub> for <sup>18</sup>F-flotufolastat was lower than that previously reported for <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-DCFPyL.</p>\",\"PeriodicalId\":7572,\"journal\":{\"name\":\"American journal of nuclear medicine and molecular imaging\",\"volume\":\"14 5\",\"pages\":\"337-344\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578810/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of nuclear medicine and molecular imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/INCG3525\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of nuclear medicine and molecular imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/INCG3525","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Normal-organ distribution of PSMA-targeting PET radiopharmaceutical 18F-flotufolastat: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies.
Background: High-affinity radiohybrid PSMA-targeting radiopharmaceutical 18F-flotufolastat (18F-rhPSMA-7.3) is newly approved for diagnostic imaging of prostate cancer. Here, we conduct a post hoc analysis of two phase 3 studies to quantify 18F-flotufolastat uptake in a range of normal organs.
Methods: All 718 evaluable 18F-flotufolastat scans from LIGHTHOUSE and SPOTLIGHT were re-evaluated. Additionally, patients' medical records were reviewed and any patients with high tumor burden (PSA>20 ng/mL), altered biodistribution (e.g., chronic kidney disease), major anatomical changes to normal organs (e.g., nephrectomy), or any other history of cancer were excluded. A medical physicist defined volumes of interest over specific organs for evaluation of SUVmean and SUVpeak per PERCIST 1.0 criteria. Normally distributed data are reported as mean (SD) and non-normally distributed data as median (IQR). The co-efficient of variation (CoV; calculated as SD/mean for normally distributed data and IQR/median for non-normally distributed data) was used to quantify variability of SUV metrics.
Results: In total, scans from 546 patients (244 primary, 302 recurrent) were eligible for this analysis. All organs were considered to be normally distributed except for the bladder and spleen. In the liver, the mean SUVmean was 6.7 (SD 1.7), CoV 26%, while the bladder median SUVmean was 10.6 (IQR 11.9), CoV 112%. The mean SUVpeak in the liver was 8.2 (SD 2.1), CoV 26% and median SUVpeak in the bladder was 16.0 (IQR 18.5), CoV 116%.
Conclusions: Physiological 18F-flotufolastat uptake in normal organs was broadly consistent with other renally-cleared radiopharmaceuticals, which may have clinically significant implications when considering patient selection for radioligand therapy. Additionally, the bladder median SUVpeak for 18F-flotufolastat was lower than that previously reported for 68Ga-PSMA-11 and 18F-DCFPyL.
期刊介绍：
The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
